Genmab — December 2022

[Bulder]

GB: I think they should discuss the general issue with risk of infections and bispecifics.

[E_L]

at the same time, according to Dr Chari: “If you measure Covid antibodies, patients on [talquetamab] are producing antibodies. That’s a really different signal than what we’ve seen before.”

[Bulder]

Ye s, but as he says, it is tragic to loose a cr- patient to covid. I would like to hear if they can come up with something to avoid infections.

[Bulder]

Does anybody know when hex38 will be presented.

[E_L]

tonight https://ash.confex.com/ash/2022/webprogram/Paper159116.html

[E_L]

but it is a poster, so you have to hope someone will post something on twitter, we'll probably have to wait for the R&D

[E_L]

rest of the schedule by the way: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual

[ProinvestorNEWS]

ASH tråd. Fyld gerne på: https://www.proinvestor.com/boards/108608/

[Solsen]

Rafineret teknologi viser gode resultater. Dejligt med de mange fremskridt i cancerbehandling https://www.bbc.com/news/health-63859184

[Bulder]

Ham her har visse indvendinger imod talq-studiet: https://www.youtube.com/watch?v=PAvLpjVstOk

[Helge_LarsenPI-redaktør]

Den første del af kritikken er svært for lægmand at vurdere. Håber at nogen af vore eksperter kan byde ind. Det med det uetiske med den homøopatiske dosering i lavdosisgruppen er til gengæld nemt for de fleste at forstå og være enig i. Det er jeg i hvert fald.

[Bulder]

Han er i hvert fald ikke begejstret for car-t. Og så peger han også på bivirkninger. Infektioner af tec og udslet på huden af talq. Men som han selv siger, der er en pris at betale. Om man skulle gå direkte til randomiserede studier fra fase 1, kan jeg ikke vurdere. Men hvis det var muligt, ville fda vel have krævet det.

[peter12]

Prasad er vist en lidt kontroversiel person https://tuftsdaily.com/news/2022/03/08/controversial-oncologist-dr-vinay-prasad-disavowed-by-dean-lectures-to-gsbs/

[GeorgeBest]

Epcoritamab+RDHAX/C: quickly effective and well tolerated in rrDLBCL in the EPCORE NHL-2 study https://twitter.com/amniebla/status/1601982162168954882?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

[GeorgeBest]

Epcoritamab CD20×CD3 with DHAX, n=29, 66% primary refractory, 21 pts responded and 16 proceeded to AutoSCT, ORR 85%, 67% CR https://twitter.com/abhinav_deol/status/1601981658252836866?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

[GeorgeBest]

sc Epcoritamab+R-DHAC/X
in RR DLBCL ASCT eligible
Ph 1/2
N=29 58y (28-75)
16 pts had ASCT after 3 cycles
5 continued epco without ASCT

CR 81% in ASCT pts 45% in no ASCT
Short Fu 12.6 mo PFS NR

V active combo (more than Pola-RICE) https://twitter.com/pallawitorkamd/status/1601981858778329088?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

[GeorgeBest]

Promising activity of Epcoritamab + RDHAX/C in transplant eligible DLBCL. ORR 85%, and CR 67%. mPFS and OS not reached. This could be a potential bridging regimen. https://twitter.com/dipenkmodi/status/1601982359041380352?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

[GeorgeBest]

Improvement in the quality of response to salvage CIT adding Epcoritamab in DLBCL patients eligible for HDT/ASCT https://twitter.com/asernapareja/status/1601982543502446592?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

[GeorgeBest]

Impressive results with Epcoritamab in r/r DLBCL high response rate & excellent PFS/OS https://twitter.com/drmiguelperales/status/1601982759920173063?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

[GeorgeBest]

epcoritamab again looks like the one to beat. 21 May 2023 Pdufa date. Meanwhile, $RHHBY due to file glofitamab by YE 2022. $REGN presenting odronextamab data at #ASH22 right now. Can step-up dosing mitigate the tox here? https://twitter.com/jacobplieth/status/1601983713176391683?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ